RESUMO
A commercial line blot using recombinant antigens was compared with a commercial ELISA and 'in-house' IFA (reference test). Two panels were evaluated: Panel A was selected to distinguish between primary infections (89), past infections (20) and seronegatives (8) in immunocompetent individuals. In panel B, patients with a high number of reactivations were included: immunosuppressed patients (37), lymphoma (19), nasopharyngeal carcinoma (10), chronic fatigue syndrome (14). Blood donors (43) and cross-reactive sera (29) were added as controls. Line blot and IFA were concordant in 94% of primary infections, 100% of seronegatives and 100% of past infections, similar to ELISA. Results differed significantly with regard to reactivations. When compared with IFA, the incidence of reactivations was overestimated by the blot, 24 and 58% in blood donors and cross-reactive sera, respectively. ELISA showed a similar problems with 21 and 34% indeterminate results, respectively. The line blot is easy to carry out, has a good concordance with the reference IFA for primary infections, and is, therefore, a sufficient choice for distinguishing primary infection from seronegative and past infection. EBV reactivation assessment will require other methods such as EBV viral load.
Assuntos
Anticorpos Antivirais/sangue , Infecções por Vírus Epstein-Barr/sangue , Herpesvirus Humano 4/imunologia , Doença Aguda , Carcinoma/sangue , Síndrome de Fadiga Crônica/sangue , Humanos , Immunoblotting/métodos , Hospedeiro Imunocomprometido , Mononucleose Infecciosa/sangue , Linfoma/sangue , Neoplasias Nasofaríngeas/sangue , Testes SorológicosRESUMO
A new immunoblot assay, composed of four Epstein-Barr virus (EBV)-encoded recombinant proteins (virus capsid antigen [VCA] p23, early antigen [EA] p138, EA p54, and EBNA-1 p72), was compared with an immunofluorescence assay on a total of 291 sera. The test was accurate in 94.5% of cases of primary EBV infection, while an immunoglobulin G anti-VCA p23 band with strong intensity correlated with reactivation.
Assuntos
Antígenos Virais/imunologia , Infecções por Herpesviridae/diagnóstico , Infecções por Herpesviridae/virologia , Herpesvirus Humano 4/isolamento & purificação , Immunoblotting/métodos , Infecções Tumorais por Vírus/diagnóstico , Infecções Tumorais por Vírus/virologia , Antígenos Virais/análise , Herpesvirus Humano 4/imunologia , Humanos , Proteínas Recombinantes/análise , Proteínas Recombinantes/imunologia , Sensibilidade e Especificidade , Testes Sorológicos/métodosRESUMO
The polyp of the ureter is a tumour which originates in the connective tissue and is covered by normal urothelium. Radical surgery is justified in some of these urothelial tumours but one should also consider a more conservative attitude when one deals with a benign fibro-epithelial polyp of the ureter especially when they are located in the lower or upper third of the ureter. We present two cases, one which represents the eleventh case of benign fibro-epithelial polyp described in children in the literature.
